Singula Bio is a seed-stage biotechnology company that was spun out of the University of Oxford. The company is focused on developing novel neoantigen-based cell therapies for patients with solid tumours. Singula Bio aims to become a world leader in providing individualised cell therapies for cancer. We have developed immunological, medical, surgical and computational technologies to develop selective therapies for difficult-to-treat solid malignancies such as ovarian cancer.
Company Details
- Employees
- 8
- Address
- John Radcliffe Hospital, Oxford,ox3 9ds,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://singulabio.com/
- HQ
- Oxford
Singula Bio Ltd. Questions
Singula Bio Ltd.'s website is https://singulabio.com/
Singula Bio Ltd.'s LinkedIn profile is https://uk.linkedin.com/company/singula-bio
Singula Bio Ltd. has
8 employees.
View email and phone details for 8
employees at Singula Bio Ltd..
Singula Bio Ltd.'s industry is
Biotechnology Research
Singula Bio Ltd.'s top competitors are
Pinetree Therapeutics Inc,
Accession Therapeutics Limited,
Upyther,
Duo Oncology,
Omideon Limited,
Lassogen, Inc.,
Aoa Dx,
Incyclix Bio,
Biovaxys Technology Corp.,
Bioarchitech Ltd.
Singula Bio Ltd.'s categories are Biotechnology Research
